ALVAC-HIV

also known as vCP205 · vCP2438 · MN120TMG · vCP1433 · vCP1452 · vCP1521

Developed for: HIV infectious disease
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · U.S. Army Medical Research and Development Command · Walter Reed Army Institute of Research (WRAIR) · ANRS, Emerging Infectious Diseases · Aventis Pharmaceuticals · French National Agency for Research on AIDS and Viral Hepatitis
+2 more
· Merck Sharp & Dohme LLC · National Institutes of Health (NIH)

Trials 8

today NCT01931358 · Ph 2 NCT01435135 · Ph 2 NCT00076063 · Ph 1/2 NCT00894114 · Ph 1 NCT00196651 · Ph 2 NCT00004579 · Ph 1 NCT00001055 · Ph 1

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT00894114	May 2003 → Jun 2009	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00004579	Apr 1998 → ?	HIV infectious disease	Walter Reed Army Institute of Research (WRAIR)	Completed	No outcome recorded
Phase 1	NCT00001055	? → Nov 1997	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00013572	—	HIV infectious disease	Walter Reed Army Institute of Research (WRAIR)	Unknown	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00076063	Mar 2004 → Mar 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT01931358	Sep 2013 → Dec 2021	HIV infectious disease	U.S. Army Medical Research and Development Command	Unknown	Mixed
Phase 2	NCT01435135	Apr 2012 → Jul 2021	HIV infectious disease	U.S. Army Medical Research and Development Command	Unknown	No outcome recorded
Phase 2	NCT00196651	Aug 2000 → Feb 2004	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Comparator or background therapy5 trials
Phase 1	NCT02109354 Comparator	Jun 2013 → Feb 2015	HIV infectious disease	HIV Vaccine Trials Network	Completed	No outcome recorded
Phase 1/2	NCT03122223 Comparator	Jan 2018 → Jul 2020	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT03284710 Comparator	Jun 2017 → Dec 2019	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT02404311 Comparator	Feb 2015 → Aug 2018	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2/3	NCT02968849 Comparator	Oct 2016 → Nov 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	ALVAC-HIV	“boosts of ALVAC-HIV (vCP1433) and LIPO-6T followed by interleukin-2 (Vac-IL2 group)” PMID 17919105 ↗ Sep 2007 12 NCT03284710 ↗ NCT00894114 ↗ NCT02968849 ↗ NCT00013572 ↗ NCT01931358 ↗ NCT00001055 ↗ NCT02109354 ↗ NCT00004579 ↗ NCT03122223 ↗ NCT00076063 ↗ Show 2 more sources
Known as	MN120TMG	“ALVAC-HIV MN120TMG (vCP205)” NCT00004579 ↗ 1 “ALVAC-HIV MN120TMG (vCP205)” NCT00001055 ↗
Known as	vCP1433	“boosts of ALVAC-HIV (vCP1433) and LIPO-6T followed by interleukin-2 (Vac-IL2 group)” PMID 17919105 ↗ Sep 2007
Known as	vCP1452	“ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.” NCT00076063 ↗
Known as	vCP1521	“The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition.” PMID 32035516 ↗ Feb 2020
Known as	vCP205	“ALVAC-HIV MN120TMG (vCP205)” NCT00004579 ↗ 3 “ALVAC-HIV MN120TMG (vCP205)” NCT00001055 ↗ “ALVAC-HIV MN120TMG (vCP205)” NCT00013572 ↗ “ALVAC-HIV (vCP205) Vaccine” NCT00894114 ↗
Known as	vCP2438	“a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost” PMID 38502656 ↗ Mar 2024 2 “ALVAC-HIV (vCP2438)” NCT02968849 ↗ “ALVAC-HIV (vCP2438)” NCT03122223 ↗
Modality	Vaccine	“ALVAC-HIV vCP205 is a second generation candidate vaccine” NCT00001055 ↗
Route	Intramuscular	“administered ALVAC-HIV or placebo by intramuscular injection” PMID 21949699 ↗ Sep 2011